Skip to main content
Medical Reference · Condition Monograph

Chronic Inflammatory Demyelinating Polyneuropathy

만성염증성탈수초성다발신경병

An immune-mediated disease in which the myelin sheath of the peripheral nerves is chronically damaged, causing muscle weakness and sensory abnormalities that progress slowly or relapse. Function can be maintained and recovered with consistent immunotherapy.

History

Chronic inflammatory demyelinating polyneuropathy is a representative chronic autoimmune neuropathy of the peripheral nerves, characterized by progression over weeks to months or by repeated cycles of improvement and worsening. Before this disease was established as a distinct condition, it was mixed into broad categories such as "chronic paralysis of unknown cause" and "relapsing polyneuritis." As nerve conduction study techniques advanced, observations accumulated that "a pattern in which the myelin sheath of the nerve is stripped away (demyelination)" was seen repeatedly and that the clinical features also showed a consistent pattern, and the concept of the disease was defined.

Historically, there were two important turning points. First, it became clear that there is a group of patients who closely resemble those with the acutely progressing Guillain-Barré syndrome, but whose period of progression is longer, at 8 weeks or more, and who can relapse. For this reason, the description that it is close to "a chronic form of Guillain-Barré syndrome" was naturally attached. Second, as evidence accumulated that a considerable number of patients respond to immunotherapy, the perception of it as "a treatable chronic neurological disease" was strengthened. Treatments such as steroids, immunoglobulin, and plasma exchange successively became established as standard treatments, and later, maintenance treatment strategies to reduce relapses and lower long-term side effects were developed.

Recent research emphasizes that this disease cannot be explained by a single cause and mechanism alone, that in some patients autoantibodies targeting a specific junctional region of the nerve (around the node of Ranvier) are identified, and that in these cases the treatment response and course are different. The view that different subcategories may be mixed together even under the name "chronic inflammatory demyelinating polyneuropathy" is spreading.

Causes

The fundamental cause of this disease is an autoimmune reaction in which the immune system fails to recognize the peripheral nerves as part of one's own body and attacks them. The targets of the attack here are mainly the myelin sheath and the Schwann cells that produce it, or the important connection region through which nerve signals are transmitted (around the node of Ranvier). When the myelin sheath is damaged, electrical signal transmission slows or is interrupted, resulting in muscle weakness and sensory abnormalities.

Why this autoimmune reaction begins differs from patient to patient, and it is still difficult to sum it up completely in one sentence. There are reports that an infection may precede it in some cases, but this differs from the pattern of Guillain-Barré syndrome, in which "a clear preceding infection" is identified in most cases. A temporal association with pregnancy and childbirth (increased risk of relapse) or an association with human immunodeficiency virus infection is also mentioned. In reality, however, "a single specific triggering event" cannot be found in many patients.

Other causes that produce symptoms similar to this disease are also important. Diabetes, vitamin deficiency, thyroid disease, drugs and toxins, hereditary neuropathy, blood disorders (such as increased monoclonal protein), and structural diseases that compress nerves can produce similar forms of numbness and weakness. Recent research emphasizes that misdiagnosis is common and explains that the process of ruling out other causes before concluding that the cause is "autoimmune" is the core of actual diagnosis.

Genetic Epidemiology

Genetic epidemiology is the perspective of examining how heredity is involved in disease risk. Chronic inflammatory demyelinating polyneuropathy is closer to an acquired immune disease than to a "hereditary disease." That is, it is difficult to regard it as a disease that inevitably occurs because of one specific gene.

However, this does not mean that family history has no significance at all. Recent research mentions the possibility that, in certain subgroups, particularly those with autoantibodies targeting nerve junctional proteins, genetic background (the combination of genes that determines the immune response) may be strongly associated. It is emphasized that in these patient groups, patterns are observed in which symptoms are more distinctive, the response to the existing standard treatment (immunoglobulin) is weak, and the response to other immunotherapies (e.g., treatments that reduce B cells) is better.

In current clinical practice, the use of genetic testing to predict "whether this disease will develop" or to directly decide treatment has not been standardized. It is realistic to understand the practical message of genetic epidemiology as roughly "in some subgroups the genetic predisposition may be more evident, and in the future the way may open toward personalized treatment by further subdividing patient groups."

General Epidemiology

Chronic inflammatory demyelinating polyneuropathy is not a common disease, but it is mentioned as the most representative disease among chronic inflammatory neuropathies. The number of patients (prevalence) varies greatly from study to study; this is partly due to differences between countries and healthcare settings, but above all it is linked to the fact that diagnostic criteria can differ and misdiagnosis and overdiagnosis are common.

It is known to be more common after middle age, and many reports indicate that it is slightly more common in men than in women. Clinically, the criterion of "a peripheral nerve abnormality that progresses for 8 weeks or more or that relapses" is important, and this distinguishes it from Guillain-Barré syndrome, in which symptoms begin suddenly and reach their peak within a few weeks.

The important point in epidemiology is that "it is treatable, but diagnostic delay and misdiagnosis can greatly lower quality of life." If it is not properly diagnosed, a person may receive unnecessary treatment for a long time (increasing side effects), or conversely, the time when treatment is needed may be missed and nerve damage may accumulate. Recent research emphasizes that efforts to standardize diagnostic criteria (clinical + electrophysiological + supportive findings) and the assessment of treatment response are the key to reducing misdiagnosis.

Pathogenesis

Pathogenesis explains how the immune system damages the nerves. In peripheral nerves, the myelin sheath surrounds the axon through which electrical signals pass, and the electrical signal "jumps" across the gaps between segments of myelin (nodes of Ranvier) and is transmitted rapidly. In this disease, this structure comes under immune attack, so the myelin sheath is stripped away or the adhesive structures around the nodes are disrupted, slowing and interrupting signal transmission. As a result, muscle weakness, reduced sensation, and balance disturbances appear.

Pathologically, findings have been reported in which inflammatory cells (especially macrophages) enter the nerve and remove the myelin sheath as if eating it away. This intuitively explains the disease name, "inflammation strips away the myelin." The view has also been presented that immune proteins such as antibodies and complement can attach to the nerve surface and strengthen the inflammatory reaction.

Recent research considers that this disease may not operate through a single mechanism alone. In some patients, T cell-centered inflammation may be stronger, and in others, antibody-centered responses may be stronger. In particular, it is emphasized that the subgroup in which specific autoantibodies against proteins around the node of Ranvier are identified may damage nerve function in a form different from "demyelination" in the traditional sense, and that the response to standard treatment may also differ. This diversity is linked to the clinical reality that "even with the same disease name, the treatment response differs greatly from person to person."

Symptoms

The most common symptoms are weakness, numbness, and dulled sensation appearing in the arms and legs at the same time. In particular, it often starts in the legs, making walking and climbing stairs difficult, and over time hand strength also declines, so buttoning, using chopsticks, and gripping objects may become difficult. One of the features of this disease is that "muscles close to the trunk (around the thighs and shoulders)" can also become weak. Therefore, it may appear as difficulty getting up from a chair or difficulty raising the arms.

Sensory symptoms may appear as numbness in the toes and fingertips, reduced sensation, a feeling that the feet cannot properly feel the floor, and a feeling of unsteady balance. When deep sensation (joint position sense) declines, swaying when the eyes are closed may become prominent. Neuropathic pain is sometimes present, but in some cases the pain is not severe and numbness and weakness are the main features.

The course differs from person to person. In some cases it only worsens gradually, and in others it shows a relapsing-remitting pattern of improving and then worsening again. Fatigue is very common, and it may appear as a mixture of not only fatigue resulting simply from weak muscles, but also the effects of the immune disease itself and long-term treatment.

Signs

The most common sign is decreased or absent tendon reflexes. The knee reflex and ankle reflex are often weakened. On muscle strength testing, symmetric muscle weakness is common, but in some variants, asymmetric weakness may appear according to the distribution of specific nerves.

On sensory testing, reduced sensation starting from the toes, reduced vibration sense, and reduced position sense may appear, making walking unstable. In severe cases, the foot cannot be lifted, leading to a dragging gait, or fine hand movements decline. Some patients also have tremor; recent research explains that in a subgroup with specific autoantibodies, tremor may be more prominent and the response to immunoglobulin may be poor.

Another important sign is muscle atrophy. In the early stage, functional decline is mainly the central feature, but if diagnosis is late or treatment is delayed, axonal damage accumulates in addition to myelin damage, and the muscles may become thin. This can be a factor that makes recovery slow or complete recovery difficult.

Screening

This disease is not one for which "population screening" targeting the general population has been established. Instead, quickly suspecting it in clinical practice when encountering "numbness and weakness of the arms and legs that persist for 8 weeks or more or that relapse" serves as de facto screening.

Primarily, the medical interview and neurological examination play the role of screening tests. It is checked whether the duration of symptoms is 8 weeks or more, whether there are relapses and remissions, whether there is weakness of muscles close to the trunk, whether reflexes are decreased, and whether there are balance problems. In particular, if the symptoms cannot be explained only by a "length-dependent" pattern that rises slowly from the toes, as in diabetic neuropathy, or if muscle weakness is noticeable, evaluation is pursued more actively.

Another key to screening is "checking to avoid misdiagnosis." Recent research emphasizes that because there are many conditions with similar symptoms (spinal disease, hereditary neuropathy, vitamin deficiency, monoclonal protein-related neuropathy, etc.), this disease should not be concluded from numbness alone, but should be differentiated with electrophysiological tests and blood tests.

Diagnosis

The diagnosis is made by combining the clinical features with electrophysiological tests. The key is to objectively confirm that the peripheral nerves show a "demyelinating" pattern. On nerve conduction studies, nerve signals slow down, and changes may appear in which signals are not transmitted well in certain segments (conduction block) or waveforms spread out. These findings suggest "a myelin problem."

However, electrophysiological testing alone does not settle everything. Recent research points out that misdiagnosis is common and that in variant forms, electrophysiological findings may not be typical or may be ambiguous in the early stage. Therefore, the diagnosis is made by taking the clinical features (progression for 8 weeks or more or relapse, muscle weakness and reduced sensation, decreased reflexes) as the foundation and adding electrophysiological tests and supportive findings to raise the probability.

As supportive tests, an increase in protein on cerebrospinal fluid testing can be helpful, and enlargement and contrast enhancement of the nerves or nerve roots on nerve ultrasound or magnetic resonance imaging can be supportive clues. Nerve biopsy is not performed in all patients, but it may be considered when the diagnosis is unclear or when other causes need to be ruled out.

In some patients, testing for specific autoantibodies can be helpful. Recent research emphasizes the principle "if treatment is not working well, recheck the diagnosis," because when antibodies targeting proteins around the node of Ranvier are identified, a treatment response different from that of traditional CIDP (weak effect of immunoglobulin, response to B cell-targeted therapy) may appear.

Treatment

The goals of treatment are to stop worsening, restore function, reduce relapses, and minimize long-term side effects. As first-line treatment, intravenous immunoglobulin, steroids, and plasma exchange are widely used. Intravenous immunoglobulin can take effect relatively quickly, and plasma exchange can induce short-term improvement by removing pathological antibodies and inflammatory mediators from the blood. Many patients respond to steroids, but with long-term use, side effects such as weight gain, osteoporosis, worsening blood sugar control, and infection risk must be considered.

Maintenance treatment is designed differently for each patient. When relapses are frequent or the condition worsens when treatment is stopped, strategies such as repeating immunoglobulin at regular intervals, or tapering steroids while combining them with other immunosuppressants, are sometimes used. Recent research also presents the view that subcutaneous immunoglobulin is useful as maintenance treatment in some patients and may reduce systemic side effects.

Recent research explains that targeted therapies related to the mechanism of action of immunoglobulin are being developed. A treatment has emerged that blocks the receptor that holds immunoglobulin so that it is not broken down in the body, thereby reducing pathological antibodies more quickly, and it may become a new option in certain patient groups. It is also emphasized that in subgroups with specific autoantibodies, treatments that reduce B cells (such as rituximab) may be more effective.

Rehabilitation is also a major pillar of treatment. It is important to restore daily function and reduce falls through strength and balance training, walking aids, and hand function training.

Prognosis

The prognosis is highly variable. Some people respond well to treatment and recover function substantially, while others have frequent relapses and need long-term treatment. Some stabilize naturally over time, but this is not easy to predict.

An important factor determining prognosis is "the timing of diagnosis and treatment." If treatment is delayed and axonal damage accumulates, recovery is slow and lasting aftereffects are more likely. Also, if a person receives unnecessary treatment for a long time due to misdiagnosis, side effects increase, and conversely, if needed treatment is not received, functional decline may progress. Recent research emphasizes that reducing misdiagnosis and standardizing response assessment are the key to improving prognosis.

Clinically, residual weakness, reduced sensation, tremor, and fatigue may persist for a long time. Limitations such as "I can walk, but I tire rapidly when I walk for a long time, and my hands have become clumsy, so my everyday pace has slowed" are common. Therefore, it is more realistic for prognostic assessment to include not only muscle strength but also walking, hand function, fatigue, and quality of life.

Prevention

There is no perfect method of prevention. This is because it is not a disease in which a clear single triggering factor, such as infection, is identified in most cases, and malfunction of the immune system is central. Therefore, it is more realistic to frame prevention as closer to "reducing worsening and aftereffects" than "preventing the onset itself."

The most important method of prevention is early recognition and early medical care. If there are numbness and weakness lasting 8 weeks or more, relapses and remissions, weakness of muscles close to the trunk, decreased reflexes, or balance disturbances, a neurological evaluation should be obtained promptly. In particular, if time passes while the condition is assumed to be spinal disease or diabetic neuropathy, the time for treatment may be missed.

For people who have already been diagnosed, "preventing relapse" is the key. Rather than stopping treatment abruptly, it is safer to taper and adjust it slowly while monitoring symptoms and functional assessments. General health management such as infection prevention, vaccination, exercise, nutrition, and sleep management is also important, but above all, lifestyle adjustments that reduce drug side effects (especially steroid side effects) and fall risk determine the long-term prognosis.

Recent research emphasizes that, because treatment strategies may differ for subgroups with specific autoantibodies, rechecking the diagnosis and redesigning treatment when the treatment response is poor or the course is unusual constitutes "personalized prevention."

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.